NTRK Fusion Cancer Clinical Trials — TRK Inhibitor Pipeline 2026

FDA-Approved TRK Inhibitors

Active Phase 2/3 Trials

The Biology: Why NTRK Fusions Are Ideal Drug Targets

NTRK fusions occur when one of three neurotrophin receptor kinase genes (NTRK1 encoding TRKA, NTRK2 encoding TRKB, NTRK3 encoding TRKC) is disrupted by a chromosomal rearrangement that fuses the kinase domain to a partner gene's promoter region. The fusion protein retains an active kinase domain but loses the ligand-binding extracellular domain, resulting in constitutive kinase activity independent of ligand stimulation — a classical oncogenic driver mechanism.

What makes NTRK fusions particularly amenable to TKI therapy:

• Driver fusions, not passenger alterations: Unlike some genomic alterations that are passengers in cancer evolution, NTRK fusions are typically early, founding events in tumor development. This means the cancer is genuinely "addicted" to TRK signaling, and TRK inhibition produces dramatic responses — not just modest disease control.
• No concurrent competing drivers: NTRK fusion-positive tumors rarely co-harbor other driver alterations (KRAS, BRAF, EGFR). The absence of alternative escape pathways contributes to the high and durable response rates seen with TRK inhibitors.
• Tumor type-agnostic relevance: The same drug (larotrectinib) produces ~75% ORR regardless of whether the tumor is a secretory carcinoma, a sarcoma, a papillary thyroid cancer, or a colon cancer. This tumor-agnosticism is rare in targeted oncology and was the scientific basis for FDA's first tumor-agnostic solid tumor approval.

NTRK Prevalence by Tumor Type

The Resistance Problem: What Happens After TRK Inhibitors

Despite remarkable initial responses, most patients on larotrectinib or entrectinib ultimately develop acquired resistance. On-target resistance mechanisms — point mutations in the TRK kinase domain — account for approximately 70% of resistance cases:

• Solvent-front mutations: G595R (NTRK1), G623R (NTRK2), G696R (NTRK3) — these mutations at the kinase gatekeeper position sterically impede larotrectinib and entrectinib binding.
• xDFG mutations: G667C (NTRK1), G693R/C (NTRK2), G709R (NTRK3) — mutations in the DFG motif that destabilize the drug-binding conformation.
• F589L mutation (NTRK1): Reduces larotrectinib binding affinity without affecting enzymatic activity.

Repotrectinib (Augtyro) was specifically designed with a macrocyclic scaffold to overcome G595R and G667C mutations — the most common resistance mutations. In the TRIDENT-1 trial, repotrectinib showed ORR of ~58% in TRK inhibitor-naïve patients and ~40% in patients with G595R/G667C resistance mutations who had previously received larotrectinib or entrectinib.

Selitrectinib (LOXO-195, Eli Lilly) is another second-generation TRK inhibitor with demonstrated activity in acquired resistance mutations — particularly the solvent-front mutations. It remains in Phase 2 (NCT03215511) and has not received FDA approval, positioning it as a potential third option in the resistance landscape if approved.

Pediatric Focus: Why NTRK Matters Disproportionately in Children

NTRK fusions are detected at dramatically higher rates in pediatric solid tumors than in adult cancers. In infantile fibrosarcoma — a cancer arising in infants and young children — ETV6-NTRK3 fusion is present in over 90% of cases. Historically, this tumor required intensive chemotherapy or limb-amputation surgery. Larotrectinib's pediatric approval (the SCOUT trial) transformed this: children with infantile fibrosarcoma now achieve ~90% ORR with an oral TKI, often avoiding surgery.

The pediatric-specific implications extend beyond fibrosarcoma:

• Pediatric high-grade gliomas (including diffuse intrinsic pontine glioma, DIPG) harbor NTRK fusions in 5-10% of cases — a meaningful subset in a cancer with no effective therapy.
• Congenital mesoblastic nephroma (neonatal kidney tumor) is nearly universally ETV6-NTRK3 positive.
• Infantile inflammatory myofibroblastic tumor often harbors NTRK or ALK fusions.

The larotrectinib pediatric basket trial (SCOUT, NCT02637687) is the evidence base for pediatric use and continues to enroll, collecting long-term durability data in this population.

Testing and Companion Diagnostics

NTRK fusion detection requires specific molecular testing — NTRK fusions are not identified by sequencing hotspot mutations and are typically missed by basic NGS panels that only cover mutation hotspots. Approved and validated testing approaches include:

• RNA-based NGS fusion panels: Preferred for sensitivity in detecting fusions. FoundationOne CDx (Foundation Medicine) and MSK-IMPACT include NTRK fusion detection and are FDA-approved CDx for larotrectinib and entrectinib.
• FISH (fluorescence in situ hybridization): Can detect NTRK rearrangements but cannot identify the specific fusion partner — less informative for treatment decisions.
• Pan-TRK IHC: A rapid screening test using antibody EPR17341 (pan-TRK, Abcam) is highly sensitive for ETV6-NTRK3 fusions in fibrosarcoma and secretory carcinoma. Used as a screening tool to identify cases that warrant confirmatory RNA NGS testing.

The testing landscape shapes the market: universal NGS testing is now standard-of-care in NSCLC and increasingly in colorectal cancer, meaning NTRK fusions are identified systematically. In rare histologies (salivary gland secretory carcinoma, fibrosarcoma), pan-TRK IHC screening is the more cost-effective initial test given the high prevalence.

Combination Strategies in Development

• TRK inhibitor + MEK inhibitor: Off-target resistance via RAS-MAPK bypass activation is addressed by combining TRK inhibition with MEK inhibitors. Preclinical combinations (larotrectinib + cobimetinib, selitrectinib + trametinib) are informing early Phase 1 trials.
• TRK inhibitor in perioperative setting: NCT05118022 explores larotrectinib as adjuvant therapy after resection of NTRK fusion-positive solid tumors — analogous to adjuvant osimertinib in EGFR-mutant NSCLC. If positive, this substantially expands the treatable population beyond advanced/metastatic settings.
• TRK inhibitor + immunotherapy: Rationale for combination with PD-1 inhibitors in TMB-high or MSI-H NTRK fusion-positive tumors is under investigation, though no Phase 2 data exist yet.

Related Pages

• Non-Small Cell Lung Cancer Clinical Trials
• Thyroid Cancer Clinical Trials
• Sarcoma Clinical Trials
• Rare Disease Clinical Trials
• RET Fusion NSCLC Clinical Trials
• ROS1 Fusion NSCLC Clinical Trials
• KRAS G12C Cancer Clinical Trials

Frequently Asked Questions

How many NTRK fusion clinical trials are currently active?

As of March 2026, there are approximately 90 active NTRK fusion cancer clinical trials. Three TRK inhibitors are FDA-approved: larotrectinib (Vitrakvi, November 2018), entrectinib (Rozlytrek, August 2019), and repotrectinib (Augtyro, November 2023). Active trials focus on resistance-setting second-generation TRK inhibitors, pediatric expansions, adjuvant use, combination strategies, and basket trials that include NTRK fusion as an eligibility criterion alongside other driver alterations.

What is an NTRK fusion and which cancers have them?

NTRK fusions are chromosomal rearrangements that create oncogenic fusion proteins with constitutively active TRK kinase signaling. They occur in ~90% of infantile fibrosarcoma and mammary analogue secretory carcinoma, 2-5% of papillary thyroid cancer, and ~0.2-1% of common cancers (NSCLC, colorectal, breast). In absolute numbers, the NSCLC and colorectal populations are meaningful given the disease prevalence. Pan-cancer NGS testing is increasingly standard, enabling systematic identification.

What is the difference between larotrectinib, entrectinib, and repotrectinib?

Larotrectinib (Vitrakvi) is highly selective for TRK only — the cleanest TRK inhibitor. Entrectinib (Rozlytrek) also inhibits ROS1 and ALK, making it useful in NSCLC where these alterations can co-occur or where broader kinase coverage is desirable. Repotrectinib (Augtyro) is the next-generation inhibitor designed specifically to overcome acquired resistance mutations (G595R, G667C) that develop after larotrectinib or entrectinib treatment — the only approved option for this post-TKI setting.

What NTRK resistance mechanisms drive the pipeline?

On-target kinase domain mutations drive approximately 70% of TRK inhibitor resistance. The most clinically relevant are solvent-front mutations (G595R in NTRK1, G623R in NTRK2, G696R in NTRK3) and xDFG mutations (G667C in NTRK1). Repotrectinib and selitrectinib were both designed to retain activity against these mutations. Off-target bypass resistance (KRAS amplification, MET amplification, alternative fusion acquisition) occurs in ~30% of cases and currently has no established second-line targeted approach.